Traditional MTB test methods require weeks to deliver a definitive result. Delayed results can lead to patients being left untreated or placed on ineffective therapies. If untreated, patients may continue to spread MTB to others in the community, increasing the disease burden. Don’t they deserve better?

**Xpert® MTB/RIF**, on-demand molecular testing — an ideal solution.

- On-demand capability that empowers physicians to manage patients effectively
- As few as one negative result can be used in the decision to remove patient from respiratory isolation
- Results turn-around time in <2 hours
- Identify patients with nontuberculous mycobacteria infection in conjunction with acid fast smear

**DO YOU HAVE THE TOOLS YOU NEED?**

**THE NEW WORLD STANDARD**

Xpert® MTB/RIF, on-demand molecular testing — an ideal solution.

- On-demand capability that empowers physicians to manage patients effectively
- As few as one negative result can be used in the decision to remove patient from respiratory isolation
- Results turn-around time in <2 hours
- Identify patients with nontuberculous mycobacteria infection in conjunction with acid fast smear

---

**IMPACT ON PATIENT PATHWAY***

1 hour  →  2 hours  →  4 hours  →  1-6 weeks

Patient Presents with TB Symptoms  →  Collect Sample and Place in Isolation  →  Xpert MTB/RIF Negative  →  Remove Patient from Isolation

Xpert MTB/RIF Positive  →  Optimize Treatment & Keep in Isolation

Standard AFB Smear & Culture

- Smear neg Xpert neg
- Probable MOTT
- Optimize Treatment

- Culture neg Perform DST
- Optimize Treatment

---

* Refer to the Xpert MTB/RIF package insert for details

# MOTT: Mycobacteria Other Than Tuberculosis; DST: Drug Susceptibility Test

**Reference:**

HYPOTHETICAL PREDICTIVE VALUES FOR MTB DETECTION USING XPERT® MTB/RIF TEST PERFORMANCE VS. CULTURE

Data analysis and statistical modeling demonstrates high Negative Predictive Value (NPV) in low prevalence population as shown on the table below. Xpert MTB/RIF, in conjunction with clinical, radiographic, and other laboratory findings, aids in selecting appropriate treatment regimens.

<table>
<thead>
<tr>
<th>Prevalence of MTB Culture Positive</th>
<th>Probability of MTB Culture Negative Among</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>One Xpert MTB/RIF Not Detected</td>
</tr>
<tr>
<td>1%</td>
<td>99.90%</td>
</tr>
<tr>
<td>2%</td>
<td>99.80%</td>
</tr>
<tr>
<td>3%</td>
<td>99.70%</td>
</tr>
<tr>
<td>4%</td>
<td>99.59%</td>
</tr>
<tr>
<td>5%</td>
<td>99.48%</td>
</tr>
<tr>
<td>10%</td>
<td>98.91%</td>
</tr>
<tr>
<td>11.80%</td>
<td>98.70%</td>
</tr>
<tr>
<td>14.20%</td>
<td>98.39%</td>
</tr>
<tr>
<td>20%</td>
<td>97.59%</td>
</tr>
<tr>
<td>40%</td>
<td>93.82%</td>
</tr>
<tr>
<td>50%</td>
<td>91.01%</td>
</tr>
</tbody>
</table>

* Source: Cepheid Xpert MTB/RIF (GXMTB/RIF-US-10) Package Insert, 301-1404, Rev. B, Table 3 and 4

For In Vitro Diagnostic Use.